Quality of Life Research

, Volume 20, Issue 2, pp 255–262 | Cite as

Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials

  • Kathleen W. WyrwichEmail author
  • Neesha Harnam
  • Julie C. Locklear
  • Henrik Svedsäter
  • Dennis A. Revicki


Background and Aims

The Wilson–Cleary health outcomes model is a hypothesized pathway linking traditional clinical variables to health-related quality of life (HRQL). This study tested the application of the Wilson–Cleary model to a patient population with generalized anxiety disorder (GAD) using longitudinal clinical trial data.


These secondary analyses pooled data from three similar 8-week, placebo-controlled, double-blind, randomized, multicenter trials of quetiapine XR therapy in GAD. Relevant health assessments for the model concepts included the Clinical Global Impression-Severity of Illness, Hamilton Rating Scale for Anxiety, the Pittsburgh Sleep Quality Index and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. A lagged path model tested whether the hypothesized relationships at baseline and week 8 between the concepts of the adapted Wilson–Cleary model were consistent with the observed data.


The resulting model fit the data (RMSEA = 0.077; CFI = 0.98; NFI = 0.96) and explained 56% of the variance in overall quality of life assessment at baseline and 69% of the variance in this assessment at week 8. Moderate to strong relationships between the adjacent hypothesized concepts support the specified model.


This adapted Wilson–Cleary model for health outcomes validated in GAD should improve the understanding and usefulness of health status measurements in this condition and increase the applications of this model to other clinical trial data.


Generalized anxiety disorder Wilson–Cleary model Health-related quality of life Health assessment Path analysis Lagged model 



This work was funded by AstraZeneca.


  1. 1.
    American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press.Google Scholar
  2. 2.
    Arnold, R., Ranchor, A. V., Koeter, G. H., de Jongste, M. J., & Sanderman, R. (2005). Consequences of chronic obstructive pulmonary disease and chronic heart failure: The relationship between objective and subjective health. Social Science and Medicine, 61(10), 2144–2154.CrossRefPubMedGoogle Scholar
  3. 3.
    Astrom, A. N., & Kida, I. A. (2007). Perceived dental treatment need among older Tanzanian adults—a cross-sectional study. BMC Oral Health, 7, 9.CrossRefPubMedGoogle Scholar
  4. 4.
    Atkinson, S., Khan, A., Joyce, M., Eggens, I., Baldytcheva, I., & Brecher, M. (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. International Journal of Neuropsychopharmacology, 11(Suppl 1), 277.Google Scholar
  5. 5.
    Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder data from a randomized double-blind placebo- and active-controlled study. International Journal of Neuropsychopharmacology, 13(3), 305–320.CrossRefPubMedGoogle Scholar
  6. 6.
    Barger, S. D., & Sydeman, S. J. (2005). Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder? Journal of Affective Disorders, 88(1), 87–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Bennett, S. J., Perkins, S. M., Lane, K. A., Deer, M., Brater, D. C., & Murray, M. D. (2001). Social support and health-related quality of life in chronic heart failure patients. Quality of Life Research, 10(8), 671–682.CrossRefPubMedGoogle Scholar
  8. 8.
    Bentler, P. M., & Bonnet, D. C. (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin, 88(3), 588–606.CrossRefGoogle Scholar
  9. 9.
    Buysse, D. J., Reynolds, C. F, 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213.CrossRefPubMedGoogle Scholar
  10. 10.
    Chrischilles, E. A., Rubenstein, L. M., Voelker, M. D., Wallace, R. B., & Rodnitzky, R. L. (2002). Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism & Related Disorders, 8(3), 199–209.CrossRefGoogle Scholar
  11. 11.
    Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Earlbaum.Google Scholar
  12. 12.
    Cosby, C., Holzemer, W. L., Henry, S. B., & Portillo, C. J. (2000). Hematological complications and quality of life in hospitalized AIDS patients. AIDS Patient Care STDS, 14(5), 269–279.CrossRefPubMedGoogle Scholar
  13. 13.
    Cunningham, W. E., Crystal, S., Bozzette, S., & Hays, R. D. (2005). The association of health-related quality of life with survival among persons with HIV infection in the United States. Journal of General Internal Medicine, 20(1), 21–27.CrossRefPubMedGoogle Scholar
  14. 14.
    Demyttenaere, K., Andersen, H. F., & Reines, E. H. (2008). Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. International Clinical Psychopharmacology, 23(5), 276–286.CrossRefPubMedGoogle Scholar
  15. 15.
    Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–326.PubMedGoogle Scholar
  16. 16.
    Endicott, J., Rajagopalan, K., Minkwitz, M., & Macfadden, W. (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life. International Clinical Psychopharmacology, 22(1), 29–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Endicott, J., Russell, J. M., Raskin, J., et al. (2007). Duloxetine treatment for role functioning improvement in generalized anxiety disorder: Three independent studies. The Journal of Clinical Psychiatry, 68(4), 518–524.CrossRefPubMedGoogle Scholar
  18. 18.
    ESEMeD/MHEDEA 2000 Investigators. (2004). Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica,109(suppl 1):21–27.Google Scholar
  19. 19.
    Faravelli, C., Guerrini Degl’Innocenti, B., & Giardinelli, L. (1989). Epidemiology of anxiety disorders in Florence. Acta Psychiatrica Scandinavica, 79(4), 308–312.CrossRefPubMedGoogle Scholar
  20. 20.
    Grant, B. F., Hasin, D. S., Stinson, F. S., et al. (2005). Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine, 35(12), 1747–1759.CrossRefPubMedGoogle Scholar
  21. 21.
    Guy, W. (1976). Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology (pp. 218–222). Rockville, MD: National Institute for Mental Health.Google Scholar
  22. 22.
    Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32(1), 50–55.PubMedGoogle Scholar
  23. 23.
    Hays, R. D., Cunningham, W. E., Sherbourne, C. D., et al. (2000). Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study. American Journal of Medicine, 108(9), 714–722.CrossRefPubMedGoogle Scholar
  24. 24.
    Henning, E. R., Turk, C. L., Mennin, D. S., Fresco, D. M., & Heimberg, R. G. (2007). Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety, 24(5), 342–349.CrossRefPubMedGoogle Scholar
  25. 25.
    Heo, S., Moser, D. K., Riegel, B., Hall, L. A., & Christman, N. (2005). Testing a published model of health-related quality of life in heart failure. Journal of Cardiac Failure, 11(5), 372–379.CrossRefPubMedGoogle Scholar
  26. 26.
    Hoyer, J., Becker, E. S., & Margraf, J. (2002). Generalized anxiety disorder and clinical worry episodes in young women. Psychological Medicine, 32(7), 1227–1237.CrossRefPubMedGoogle Scholar
  27. 27.
    Hu, L. T., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling, 6(1), 1–55.CrossRefGoogle Scholar
  28. 28.
    Jöreskog, K. G., & Sörbom, D. (2006). LISREL 8.80 for Windows [Computer Software]. Lincolnwood, IL: Scientific Software International.Google Scholar
  29. 29.
    Kessler, R. C., DuPont, R. L., Berglund, P., & Wittchen, H. U. (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry, 156(12), 1915–1923.PubMedGoogle Scholar
  30. 30.
    Kessler, R. C., Keller, M. B., & Wittchen, H. (2001). The epidemiology of generalized anxiety disorder. In O. Brawman-Mintzer (Ed.), The psychiatric clinics of North America: Generalized anxiety disorder (pp. 19–40). Philadelphia: W.B. Saunders.Google Scholar
  31. 31.
    Kessler, R. C., & Wittchen, H. U. (2002). Patterns and correlates of generalized anxiety disorder in community samples. Journal of Clinical Psychiatry, 63(Suppl 8), 4–10.PubMedGoogle Scholar
  32. 32.
    Lee, D. T., Yu, D. S., Woo, J., & Thompson, D. R. (2005). Health-related quality of life in patients with congestive heart failure. European Journal of Heart Failure, 7(3), 419–422.CrossRefPubMedGoogle Scholar
  33. 33.
    MacCallum, R. C., Browne, M. W., & Sugawara, H. M. (1996). Power analysis and determination of sample size for covariance structure modeling. Psychological Methods, 1(2), 130–149.CrossRefGoogle Scholar
  34. 34.
    Masoudi, F. A., Rumsfeld, J. S., Havranek, E. P., et al. (2004). Age, functional capacity, and health-related quality of life in patients with heart failure. Journal of Cardiac Failure, 10(5), 368–373.CrossRefPubMedGoogle Scholar
  35. 35.
    Massion, A. O., Warshaw, M. G., & Keller, M. B. (1993). Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. American Journal of Psychiatry, 150(4), 600–607.PubMedGoogle Scholar
  36. 36.
    Mathisen, L., Andersen, M. H., Veenstra, M., Wahl, A. K., Hanestad, B. R., & Fosse, E. (2007). Quality of life can both influence and be an outcome of general health perceptions after heart surgery. Health Qual Life Outcomes, 5, 27.CrossRefPubMedGoogle Scholar
  37. 37.
    Merideth, C., Cutler, A., Neijber, A., et al. (2008). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder. European Neuropsychopharmacology, 18(suppl 4), S499.CrossRefGoogle Scholar
  38. 38.
    Mick, E., Faraone, S. V., Spencer, T., Zhang, H. F., & Biederman, J. (2008). Assessing the validity of the Quality of Life Enjoyment, Satisfaction Questionnaire Short Form in adults with ADHD. Journal of Attention Disorders, 11(4), 504–509.CrossRefPubMedGoogle Scholar
  39. 39.
    Norman, G., & Streiner, D. (2000). Biostatistics: The bare essentials. Toronto: Decker.Google Scholar
  40. 40.
    Olsson, I., Mykletun, A., & Dahl, A. A. (2005). The Hospital Anxiety and Depression Rating Scale: A cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry, 5, 46.CrossRefPubMedGoogle Scholar
  41. 41.
    Orfila, F., Ferrer, M., Lamarca, R., Tebe, C., Domingo-Salvany, A., & Alonso, J. (2006). Gender differences in health-related quality of life among the elderly: The role of objective functional capacity and chronic conditions. Social Science and Medicine, 63(9), 2367–2380.CrossRefPubMedGoogle Scholar
  42. 42.
    Phaladze, N. A., Human, S., Dlamini, S. B., et al. (2005). Quality of life and the concept of “living well” with HIV/AIDS in sub-Saharan Africa. Journal of Nursing Scholarship, 37(2), 120–126.CrossRefPubMedGoogle Scholar
  43. 43.
    Revicki, D. A., Brandenburg, N., Matza, L., Hornbrook, M. C., & Feeny, D. (2008). Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Quality of Life Research, 17(10), 1285–1294.CrossRefPubMedGoogle Scholar
  44. 44.
    Ritsner, M., Kurs, R., Gibel, A., Ratner, Y., & Endicott, J. (2005). Validity of an abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Quality of Life Research, 14(7), 1693–1703.CrossRefPubMedGoogle Scholar
  45. 45.
    Sheehan, D. V., Meyers, A. L., Prakash, A., et al. (2008). The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Current Medical Research and Opinion, 24(9), 2457–2466.CrossRefPubMedGoogle Scholar
  46. 46.
    Sousa, K. H., Holzemer, W. L., Henry, S. B., & Slaughter, R. (1999). Dimensions of health-related quality of life in persons living with HIV disease. Journal of Advanced Nursing, 29(1), 178–187.CrossRefPubMedGoogle Scholar
  47. 47.
    Sousa, K. H., & Kwok, O. M. (2006). Putting Wilson and Cleary to the test: Analysis of a HRQOL conceptual model using structural equation modeling. Qual Life Re, 15(4), 725–737.CrossRefGoogle Scholar
  48. 48.
    Straits-Troster, K., Fields, J. A., Wilkinson, S. B., et al. (2000). Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain and Cognition, 42(3), 399–416.CrossRefPubMedGoogle Scholar
  49. 49.
    Wettergren, L., Bjorkholm, M., Axdorph, U., & Langius-Eklof, A. (2004). Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Quality of Life Research, 13(8), 1369–1379.CrossRefPubMedGoogle Scholar
  50. 50.
    Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65.CrossRefPubMedGoogle Scholar
  51. 51.
    Wilson, I. B., & Cleary, P. D. (1996). Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Medical Care, 34(6), 610–623.CrossRefPubMedGoogle Scholar
  52. 52.
    Wilson, I. B., & Cleary, P. D. (1997). Clinical predictors of declines in physical functioning in persons with AIDS: Results of a longitudinal study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(5), 343–349.PubMedGoogle Scholar
  53. 53.
    Wittchen, H. U. (2002). Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety, 16(4), 162–171.CrossRefPubMedGoogle Scholar
  54. 54.
    Wittchen, H. U., Carter, R. M., Pfister, H., Montgomery, S. A., & Kessler, R. C. (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology, 15(6), 319–328.CrossRefPubMedGoogle Scholar
  55. 55.
    Wyrwich, K. W., Harnam, N., Revicki, D. A., et al. (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality of Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology, 24(6), 289–295.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Kathleen W. Wyrwich
    • 1
    Email author
  • Neesha Harnam
    • 1
  • Julie C. Locklear
    • 2
  • Henrik Svedsäter
    • 3
  • Dennis A. Revicki
    • 1
  1. 1.United BioSource CorporationBethesdaUSA
  2. 2.AstraZeneca Pharmaceuticals LPWilmingtonUSA
  3. 3.AstraZeneca R&DMölndalSweden

Personalised recommendations